Share on LinkedInShare on LinkedIn

ARTICLE · 18 JULY 2023

Genentech Files BPCIA Complaint Against Biogen Regarding Tocilizumab

The asserted patents cover various processes, methods of treatment, antibody subtypes, and compositions.

United StatesIntellectual Property

Yesterday, Genentech, Inc., Hoffmann-LaRoche, Inc., and Chugai Pharmaceutical Co., Ltd. ("Genentech") filed BPCIA litigation against Biogen MA Inc. and Bio-Thera Solutions, Ltd. in the District of Massachusetts. In its Complaint, Genentech asserts that Biogen is seeking FDA approval "to commercialize 'BIIB800,' a proposed biosimilar to Genentech's drug Actemra® (tocilizumab)." Genentech further asserts that "Bio-Thera manufactures BIIB800 for Biogen...and will participate in the importation of BIIB800 in to the United States."

Genentech's Complaint includes a summary of the parties interactions during the "patent dance." Specifically, Genentech asserts that the parties engaged in the "patent dance" but that Biogen failed to provide "such other information that describes the process or processes used to manufacture the biological process that is the subject of [its] application." Genentech also alleges that Biogen's detailed statements "lacked the level of detail

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from